Phytoceuticals is a life science company that develops innovative medicines from natural product extracts. The company’s current focus is to develop first-in-class solutions for major indications in dermatology. Upon receiving product registration, Phytoceuticals aims at partnering with strong industry partners for product distribution in order to maximise the potential reach and revenue for the product.
Wound-healing product for an unmet medical need
Wound-treating MDs agree that no single exogenous available agent can effectively mediate all the numerous aspects of the wound-healing process and no ‘all-round’ product for regulating wound-healing processes currently exists. For chronic wounds there is currently no completely satisfying product available.
Primary wound dressings for acute and chronic wounds
Phytoceuticals’ lead product 1 PRIMARY WOUND DRESSING® is a specially formulated mixture of Neem oil and St. John’s Wort oil. «1» is the simple, natural and effective first choice product for the treatment of acute and chronic wounds, and is effective in a broad range of wound types and wound stages. «1» has been approved in the EU as a medical device. It creates a moist wound environment and the oil layer prevents the secondary dressing from adhering to the wound. Furthermore, it has an antimicrobial effect and promotes the regeneration of the epidermis.
"These effects clearly make «1» a modern and convincing wound product of your first choice," says Prof. Thomas Hunziker, MD, University Hospital, Bern, Switzerland.
Phytoceuticals develops wound-healing products using natural product ingredients.
Phytoceuticals' lead product 1 PRIMARY WOUND DRESSING® is for the treatment of acute and chronic wounds.
Phytoceuticals' primary wound dressings target both the human and veterinary wound markets.
Wound dressings for human / veterinary wound markets
Besides the acute and chronic human wound market, Phytoceuticals is targeting the veterinary wound and human inflammatory skin disorders market with formulations derived from «1».
International commercialisation of primary wound dressings
Switzerland is Phytoceuticals’ home market and serves as an ideal test market prior to launching internationally. The Swiss market will be directly covered by the Phytoceuticals sales team starting in May 2011. In parallel to launching the product in Switzerland the company has developed customised market penetration strategies for the major international markets including the EU and the US. The international markets will ideally be served through strong distribution partners.
The 2011 Frost & Sullivan Western Europe New Product Innovation Award in Advanced Wound Management has been presented to Phytoceuticals for its 1 PRIMARY WOUND DRESSING® ('1'). This innovative wound dressing spray is specially formulated from a proprietary combination of Neem oil and St.
Phytoceuticals' new primary wound dressing, 1, is a simple, natural and effective product for the treatment of acute and chronic wounds. To discover just how easy wound care can be, visit Phytoceuticals at EWMA 2011, which is being held 25-27 May in Brussels, Belgium. Phytoceuticals wi
Phytoceuticals will present promising clinical and scientific data on 1 PRIMARY WOUND DRESSING® at the 2011 EWMA Conference on 26 May, the largest European wound management conference. The data underlines the product's first choice positioning and effective mode of action. '1' is the first p
In November 2010 Phytoceuticals received CE Marking for 1, its novel primary wound dressing, the first product that will be commercialised from the company's wound-healing platform. 1 is designed to be the first-choice dressing for acute and chronic wounds. "This European regulatory app